HOFFMAN, REBECA S,CHARTASH, ELLIOT,TAYLOR, LORI K,YAN, PHILIP,GRANNEMAN, GEORGE RICHARD
申请号：
NZ59136205
公开号：
NZ591362A
申请日:
2005.04.11
申请国别(地区):
NZ
年份:
2012
代理人:
摘要：
Provided is the use of an isolated human anti-TNF antibody or an antigen-binding portion thereof, in the manufacture of a medicament for treating a skin disorder in which TNF activity is detrimental using a multiple-variable dose regimen, said regimen, when used, comprising administering to a subject in need thereof the medicament comprising at least one induction dose of 80 to 160 mg of the antibody or antigen-binding portion thereof, within an induction phase； and subsequently administering to the subject the medicament comprising at least one treatment dose of the antibody or antigen-binding portion thereof, within a treatment phase, such that treatment occurs, wherein the induction dose is at least twice the amount of the treatment dose. The skin disorder can be psoriasis or hidradenitis suppurativa.
